PT2854768T - Composições farmacêuticas de pemetrexed - Google Patents
Composições farmacêuticas de pemetrexedInfo
- Publication number
- PT2854768T PT2854768T PT137300703T PT13730070T PT2854768T PT 2854768 T PT2854768 T PT 2854768T PT 137300703 T PT137300703 T PT 137300703T PT 13730070 T PT13730070 T PT 13730070T PT 2854768 T PT2854768 T PT 2854768T
- Authority
- PT
- Portugal
- Prior art keywords
- pemetrexed
- pharmaceutical compositions
- pharmaceutical
- compositions
- pemetrexed pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1648DE2012 | 2012-05-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2854768T true PT2854768T (pt) | 2017-05-19 |
Family
ID=48656253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT137300703T PT2854768T (pt) | 2012-05-30 | 2013-05-30 | Composições farmacêuticas de pemetrexed |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9421207B2 (pt) |
| EP (2) | EP3210629A1 (pt) |
| DK (1) | DK2854768T3 (pt) |
| ES (1) | ES2624442T5 (pt) |
| LT (1) | LT2854768T (pt) |
| PT (1) | PT2854768T (pt) |
| SI (1) | SI2854768T1 (pt) |
| WO (1) | WO2013179248A1 (pt) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160051679A1 (en) * | 2013-04-12 | 2016-02-25 | Actavis Group Ptc Ehf. | Pemetrexed Formulation |
| KR101485243B1 (ko) | 2013-05-08 | 2015-01-21 | 씨제이헬스케어 주식회사 | 안정화된 페메트렉시드 제제 |
| EP3007681A1 (en) * | 2013-06-14 | 2016-04-20 | Synthon B.V. | Stable and water soluble pharmaceutical compositions comprising pemetrexed |
| US9688682B2 (en) * | 2013-07-16 | 2017-06-27 | Dr. Reddy's Laboratories Limited | Crystalline forms of pemetrexed tromethamine salts |
| PL3040074T3 (pl) | 2013-10-03 | 2019-03-29 | Fujifilm Corporation | Preparat iniekcyjny i sposób jego wytwarzania |
| JP6120766B2 (ja) * | 2013-12-27 | 2017-04-26 | 富士フイルム株式会社 | 注射液製剤及びその製造方法 |
| WO2015145911A1 (ja) * | 2014-03-28 | 2015-10-01 | 富士フイルム株式会社 | 注射液製剤及びその製造方法 |
| US20180235969A1 (en) * | 2014-10-16 | 2018-08-23 | Synthon B.V. | Liquid pharmaceutical composition comprising pemetrexed |
| GB201418555D0 (en) * | 2014-10-16 | 2014-12-03 | Teva Gmbh | Pemetrexed formulations |
| FI4011377T3 (fi) * | 2015-02-13 | 2025-01-07 | Sun Pharmaceutical Ind Ltd | Suonensisäinen infuusioannosmuoto sisältäen pemetreksediä |
| KR101919436B1 (ko) * | 2015-05-28 | 2018-11-16 | 주식회사 삼양바이오팜 | 안정화된 약학 조성물 및 그의 제조방법 |
| GB201511246D0 (en) * | 2015-06-25 | 2015-08-12 | Actavis Group Ptc Ehf | Pharmaceutical formulation |
| KR101693675B1 (ko) * | 2015-12-14 | 2017-01-06 | 주식회사 종근당 | 페메트렉시드 또는 그의 약제학적으로 허용가능한 염을 함유하는 안정화된 약학조성물 |
| US20170239250A1 (en) | 2016-02-19 | 2017-08-24 | Eagle Pharmaceuticals, Inc. | Pemetrexed formulations |
| CA3014755C (en) * | 2016-02-19 | 2023-11-14 | Eagle Pharmaceuticals, Inc. | Stable pemetrexed formulations comprising propylene glycol |
| US20200246263A1 (en) * | 2017-08-29 | 2020-08-06 | Fresenius Kabi Oncology Limited | Stable liquid compositions of pemetrexed |
| PL3470045T3 (pl) | 2017-10-10 | 2021-03-08 | Sun Pharmaceutical Industries Ltd | Dożylna infuzyjna postać dawkowania dla pemetreksedu |
| CN108158989B (zh) * | 2018-03-01 | 2020-08-28 | 河北爱尔海泰制药有限公司 | 一种盐酸氨溴索注射液组合物 |
| US10966982B2 (en) * | 2018-11-20 | 2021-04-06 | Cipla Limited | Stable pharmaceutical formulations of pemetrexed |
| CA3137265A1 (en) * | 2019-05-01 | 2020-11-05 | Intas Pharmaceuticals Ltd. | A stable, ready to use aqueous pharmaceutical composition of pemetrexed |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| WO2021192472A1 (ja) * | 2020-03-24 | 2021-09-30 | ナガセ医薬品株式会社 | ペメトレキセド製剤 |
| JP7282065B2 (ja) * | 2020-10-05 | 2023-05-26 | イーグル ファーマシューティカルズ, インコーポレイテッド | ペメトレキセド製剤 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02502534A (ja) | 1987-12-18 | 1990-08-16 | チバ‐ガイギー アクチェンゲゼルシャフト | 1‐メチル‐β‐オキソ‐α‐(フェニルカルバモイル)‐2‐ピロールプロピオニトリルのトロメタミン塩 |
| KR0162654B1 (ko) | 1989-12-11 | 1998-11-16 | 알렌 제이. 시니스갤리 | N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체 |
| IL96531A (en) | 1989-12-11 | 1995-08-31 | Univ Princeton | History of Acid N- (Diomeric-H1-Pyrolo] D-2,3 [Pyrimidine-3-Ilacyl (-glutamic, preparation and pharmaceutical preparations containing them) |
| US6686365B2 (en) | 2000-02-04 | 2004-02-03 | Eli Lilly And Company | Pharmaceutical composition |
| ATE359823T1 (de) | 2000-06-30 | 2007-05-15 | Lilly Co Eli | Zusammensetzung, welche ein antifolate und ein methylmalonsäuresenkendes mittel enthält |
| CN100364993C (zh) * | 2003-05-30 | 2008-01-30 | 江苏恒瑞医药股份有限公司 | 培美曲噻盐及其制备方法 |
| EP1818049A3 (en) | 2006-02-10 | 2008-11-19 | LifeCycle Pharma A/S | Stabilized Atorvastatin |
| CN101081301A (zh) | 2006-05-29 | 2007-12-05 | 海南天源康泽医药科技有限公司 | 含有培美曲塞的药物组合物 |
| WO2008021411A2 (en) | 2006-08-14 | 2008-02-21 | Sicor Inc. | Processes for the preparation of lyophilized pharmaceutically acceptable salts of pemetrexed diacid |
| WO2010030598A2 (en) | 2008-09-11 | 2010-03-18 | Dr. Reddy's Laboratories Limited | Pharmaceutical formulations comprising pemetrexed |
| IT1401207B1 (it) | 2010-06-30 | 2013-07-12 | Magic Production Group S A | Dispositivo e procedimento per la chiusura di contenitori |
| JP2013540104A (ja) * | 2010-07-28 | 2013-10-31 | イーグル・ファーマシューティカルズ・インコーポレーテッド | 延長された保存安定性を有するペメトレキセドを含有する医薬組成物 |
| KR101069128B1 (ko) * | 2011-03-10 | 2011-09-30 | 건일제약 주식회사 | 페메트렉시드 또는 그의 염을 포함하는 항산화제-비함유 주사용 용액 형태의 약학적 제제의 제조방법 |
| US20160051679A1 (en) * | 2013-04-12 | 2016-02-25 | Actavis Group Ptc Ehf. | Pemetrexed Formulation |
-
2013
- 2013-05-30 DK DK13730070.3T patent/DK2854768T3/en active
- 2013-05-30 SI SI201330666T patent/SI2854768T1/sl unknown
- 2013-05-30 ES ES13730070T patent/ES2624442T5/es active Active
- 2013-05-30 EP EP17161417.5A patent/EP3210629A1/en not_active Withdrawn
- 2013-05-30 PT PT137300703T patent/PT2854768T/pt unknown
- 2013-05-30 US US14/403,310 patent/US9421207B2/en active Active
- 2013-05-30 LT LTEP13730070.3T patent/LT2854768T/lt unknown
- 2013-05-30 EP EP13730070.3A patent/EP2854768B2/en active Active
- 2013-05-30 WO PCT/IB2013/054456 patent/WO2013179248A1/en not_active Ceased
-
2016
- 2016-07-01 US US15/200,433 patent/US9968608B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2854768B1 (en) | 2017-03-22 |
| DK2854768T3 (en) | 2017-06-12 |
| ES2624442T3 (es) | 2017-07-14 |
| EP3210629A1 (en) | 2017-08-30 |
| WO2013179248A1 (en) | 2013-12-05 |
| US9968608B2 (en) | 2018-05-15 |
| US9421207B2 (en) | 2016-08-23 |
| SI2854768T1 (sl) | 2017-08-31 |
| US20150111905A1 (en) | 2015-04-23 |
| US20160310495A1 (en) | 2016-10-27 |
| EP2854768A1 (en) | 2015-04-08 |
| LT2854768T (lt) | 2017-06-12 |
| EP2854768B2 (en) | 2025-06-18 |
| ES2624442T5 (en) | 2025-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2854768T (pt) | Composições farmacêuticas de pemetrexed | |
| BR112014003052A2 (pt) | composições farmacêuticas | |
| DK2694038T3 (da) | Farmaceutisk sammensætning | |
| DK3181128T3 (da) | Farmaceutisk nilotinib-sammensætning | |
| PT3725778T (pt) | Formulações de enzalutamida | |
| FR2997014B1 (fr) | Composition sterile dermo-injectable | |
| EP2832453A4 (en) | ATOMIZERS | |
| CO6930367A2 (es) | Composiciones farmaceúticas | |
| BR112014032798A2 (pt) | composição | |
| ZA201503594B (en) | Pharmaceutical compositions | |
| ZA201501930B (en) | Pharmaceutical composition | |
| ME03413B (me) | Kompozicije које sadrže peg i askorbat | |
| HUE040370T2 (hu) | Gyógyszerkészítmények | |
| DK2822967T3 (da) | Compositions comprising secretory - like immunoglobulins | |
| DK2897594T3 (da) | Farmaceutisk sammensætning | |
| EP2832730A4 (en) | MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION | |
| DK2815752T3 (da) | Oral farmaceutisk sammensætning | |
| CL2014003283A1 (es) | Formulación farmacéutica. | |
| DK2877155T3 (da) | Opioidformuleringer | |
| EP2769718A4 (en) | MEDICAL COMPOSITION | |
| DK2854765T3 (da) | Farmaceutisk pemetrexed-opløsning | |
| BR112014032712A2 (pt) | composição | |
| HUE049445T2 (hu) | Új kompozíciók | |
| DK2811828T3 (da) | Adjuvanssammensætninger | |
| EP2837670A4 (en) | Fluorobiphenyl-containing composition |